Roll-over Study to Allow Continued Access to Ribociclib

Recruiting

Roll-over Study to Allow Continued Access to Ribociclib

Sponsor:

Novartis Pharmaceuticals

Code:

NCT05161195

Conditions

Metastatic Breast Cancer

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Ribociclib

Letrozole

Anastrozole

Goserelin

Tamoxifen

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Novartis Pharmaceuticals on 2025-05-15.